Last updated: May 15, 2026
Capreomycin sulfate is an established, older injectable antibiotic used in multi-drug regimens for drug-resistant tuberculosis (DR-TB). Public clinical development activity for capreomycin sulfate is limited in 2025: the active, high-profile pipeline focus in DR-TB has shifted toward newer TB regimens and repurposed agents with formalized, shorter-course protocols. Market analysis and forward revenue projections therefore hinge less on new capreomycin trials and more on (1) continued use in DR-TB treatment guidelines, (2) procurement patterns, and (3) supply continuity by manufacturers.
No additional drug-specific proprietary pipeline metrics can be reliably produced here without pulling live trial registries and payer-level pricing data. The rest of this brief delivers an actionable landscape: where capreomycin sits in DR-TB care, what clinical trial activity typically exists for this product class (and what to look for), how the market is likely to behave, and the exclusivity/generic risks that affect commercial longevity.
What is capreomycin sulfate used for in clinical practice?
Capreomycin sulfate is a parenteral second-line anti-tuberculosis agent. Clinically, it is used as part of combination therapy for DR-TB when susceptibility patterns and guideline recommendations support its inclusion.
What disease area and regimen role does capreomycin target?
- Indication area: Drug-resistant pulmonary tuberculosis (commonly multidrug-resistant TB settings).
- Regimen position: Background “companion” drug within combination regimens intended to prevent resistance amplification and achieve sterilizing activity over prolonged treatment.
What are the practical drivers of ongoing use?
- Susceptibility profile: Use depends on DST (drug susceptibility testing) showing retained activity.
- Tolerability constraints: In DR-TB, clinicians assemble regimens under constraints like renal toxicity, ototoxicity risk, and cross-resistance among aminoglycoside-like agents.
- Availability and procurement: DR-TB programs often use what is supply-stable and guideline-compatible.
Is capreomycin sulfate still in active clinical trials in 2025?
No complete, drug-specific clinical trials update with endpoints, enrollment, phase, and timelines can be produced in this format without verifiable, current registry pulls. In operational terms, capreomycin sulfate is more likely to show up in:
- Retrospective studies on regimen outcomes and adverse events (real-world evidence).
- Programmatic or comparative cohort studies within DR-TB national programs.
- PK/PD and dosing optimization work, usually as protocol components rather than large standalone development programs.
What trial types are most likely for capreomycin in a modern DR-TB portfolio?
- Dosing and therapeutic drug monitoring (TDM) studies to reduce nephro/ototoxicity.
- PK exposure-response analyses tied to regimen outcomes.
- Comparative effectiveness using historical controls.
- Safety-focused analyses in specific subpopulations (renal impairment, elderly, comorbidities).
What endpoints would matter if capreomycin trials restart?
- Culture conversion milestones (e.g., 2-month and end-of-treatment culture status).
- Sustained treatment success (typically end-of-follow-up).
- Time to relapse and relapse-free survival.
- Safety: nephrotoxicity incidence, ototoxicity screening outcomes, and discontinuation rates.
What clinical-trials signals should investors watch for capreomycin sulfate going forward?
For an older DR-TB injectable, “signal” is more meaningful than “novelty.” The most decision-relevant signals are:
- Inclusion in guideline-backed regimens and whether that correlates with formal program cohorts.
- Evidence that reduces toxicity (dose optimization or TDM integration).
- Supply stability that supports continued procurement.
- Randomized or prospectively designed comparative studies demonstrating benefit in specific resistance patterns.
How would a new trial change the commercial outlook?
A new trial would matter if it produces:
- A clearer place in therapy (who gets it, when it must be used).
- Lower toxicity strategies that reduce regimen discontinuations.
- Strong effectiveness in relevant resistance classes.
Without such signals, commercial trajectory typically tracks demand rather than new differentiation.
What is the capreomycin sulfate market size by use case, and who buys it?
Capreomycin sulfate’s purchasing is dominated by public-health procurement and DR-TB program budgets rather than commercial wholesalers in typical developed-market patterns.
Which buyers matter most?
- Government TB programs and ministries of health.
- International procurement agencies supporting DR-TB initiatives.
- Global health NGOs managing DR-TB drug supply chains.
- Hospital systems in high-burden regions where DR-TB care is centralized.
What determines tender volumes?
- DR-TB incidence and treatment coverage in target countries.
- Program funding cycles.
- Supply continuity from manufacturers (including risk of stock-outs).
- Guideline regimen composition based on resistance epidemiology.
How do procurement cycles shape capreomycin sulfate revenue?
For older injectables, revenue volatility is driven by:
- Tender timing and contract award calendars.
- Re-qualification of suppliers and site qualification.
- Batch availability and quality/CMC readiness.
- Switching within regimens if newer drugs replace older components.
What pattern typically emerges for older DR-TB injectables?
- High variability year to year based on tenders.
- Gradual decline risk if newer all-oral or shorter-course regimens displace injectable backbone drugs.
What is the capreomycin sulfate competitive landscape?
Capreomycin sulfate competes within DR-TB regimens on:
- Susceptibility match (can it replace other second-line injectables?).
- Safety profile relative to alternatives (aminoglycoside-like tox profiles).
- Formulation and availability (injectable presentation and supply reliability).
What alternatives most often substitute for capreomycin in DR-TB regimens?
In practice, regimen composition is influenced by the broader “second-line injectable” space and guideline frameworks. Substitution risk is greatest where newer regimens or resistance patterns reduce capreomycin’s role.
How strong is the patent estate for capreomycin sulfate and what does it mean for generics?
Capreomycin sulfate is a legacy molecule. Patent estates for older small-molecule antibiotics commonly have limited remaining life in most jurisdictions, and commercial markets often contain multiple generic and authorized suppliers.
A complete patent-strength assessment with numbered US patents, jurisdictions, claims scope, and expiration dates cannot be produced here without a live patent-family pull and Orange Book/EMA status matching. The business implication remains consistent across legacy TB antibiotics:
- If patents do not block filings or formulations, generic competition is a primary revenue overhang.
- Where manufacturing process or specific formulation constraints exist, entry can be delayed, but the product class has typically already passed this stage.
What patent categories usually matter for older injectables?
- Process patents (manufacturing route, intermediates, crystallization control).
- Formulation patents (stabilizers, reconstitution behavior, container-closure compatibility).
- Method-of-use claims tied to DR-TB regimen logic (less common for older drugs unless new clinical evidence drove new claiming).
When does capreomycin sulfate lose exclusivity, and are there Paragraph IV risks?
Specific exclusivity timelines and Paragraph IV timing cannot be stated accurately without the drug’s current US regulatory and Orange Book record for listed patents. In practice for legacy drugs:
- US market exclusivity is often already expired.
- The main “entry risk” becomes generic launch timing, supply capacity, and label competitiveness rather than litigation driven by late-filing brand patents.
What to model for generic entry risk in DR-TB injectables
- Shelf-life and stability testing timelines.
- CMO capacity for sterile manufacturing.
- Batch release lag and regulatory inspection readiness.
- Contract award preferences based on prior supplier performance.
What is the Orange Book status of capreomycin sulfate?
A verified Orange Book listing cannot be provided here without live Orange Book data. For operational planning, the key business question is whether capreomycin sulfate has:
- Approved drug-product exclusivity remaining, and
- Listed patents relevant to FDA approval.
Without verified listings, this section cannot be completed to Bloomberg-standard precision.
What FDA regulatory status affects capreomycin sulfate supply and labeling?
Capreomycin sulfate is an injectable product, so regulatory relevance typically concentrates on:
- Sterility assurance and aseptic process validation,
- Container closure and reconstitution performance,
- Label updates reflecting safety monitoring (notably renal monitoring and ototoxicity risk),
- Manufacturing facility compliance.
What events can change market availability quickly?
- Regulatory enforcement actions or inspection outcomes.
- Quality deviations that trigger batch holds.
- Supplier concentration leading to single-site supply shocks.
Capreomycin sulfate market projection: base case, downside, and upside scenarios
A numeric forecast cannot be produced without:
- Current unit demand data by geography,
- Tender forecasts and negotiated contract sizes,
- Verified pricing (ex-factory and program reimbursement),
- Country-level DR-TB program coverage trends.
What can be stated directionally for a legacy DR-TB injectable:
Base case (most likely)
- Demand stays tied to DR-TB enrollment.
- Use gradually shifts as newer regimens gain adoption.
- Revenue fluctuates with tenders and supply reliability.
- Competitive pressure continues via generics and authorized suppliers.
Downside case
- Faster displacement of injectables from guideline-preferred regimens.
- Supply interruptions from fewer manufacturing sites.
- Higher resistance patterns that reduce effective use.
Upside case
- Evidence supports capreomycin in additional resistance subgroups.
- Stable supply and procurement prioritization keeps it “default” in some programs.
- Improved tolerability/monitoring decreases discontinuation rates and makes it easier to keep in regimens.
How do clinical-trial updates translate into procurement and revenue?
In DR-TB procurement, “trial success” typically translates into revenue only if:
- Guidelines incorporate or reinforce the drug’s role,
- Programs update formularies,
- Tender specifications include the product,
- Supply is available at scale.
Absent these steps, trials can remain academically important without commercial impact.
Key Takeaways
- Capreomycin sulfate remains a legacy second-line injectable used in DR-TB regimens, with demand primarily driven by program procurement and susceptibility-based prescribing.
- 2025-specific clinical trial details cannot be reliably enumerated here without live registry validation, but the most plausible modern activity is PK/safety optimization and real-world outcomes rather than large brand-defining efficacy programs.
- Market revenue is forecast to be tender- and supply-driven, with continued generic/authorized-supplier pressure typical of older small-molecule TB antibiotics.
- Patent/exclusivity timing and Orange Book status require verified listings and cannot be stated with the precision required for business decisions in this format.
FAQs
1) What role does capreomycin sulfate play in multidrug-resistant tuberculosis regimens?
It functions as a second-line injectable antibiotic within combination therapy, selected based on drug susceptibility and tolerability constraints.
2) Are there ongoing trials comparing capreomycin to newer DR-TB regimens?
Modern DR-TB research more often includes comparative or cohort analyses around regimen outcomes, with new regimens typically shifting priority away from older injectables.
3) What safety monitoring is most important for capreomycin sulfate?
Renal monitoring and ototoxicity surveillance are core considerations, often with protocolized safety endpoints in clinical and real-world studies.
4) What drives tender demand for capreomycin sulfate in high-burden countries?
DR-TB program enrollment, guideline regimen composition, contract cycles, and supplier availability/batch release performance.
5) How does generic competition typically affect capreomycin sulfate pricing?
In legacy DR-TB injectables, multiple approved suppliers usually compress pricing and shift buyer selection toward reliability, supply capacity, and tender competitiveness.
References (APA)
- World Health Organization. (2020). WHO consolidated guidelines on tuberculosis module 4: Treatment - Drug-resistant tuberculosis treatment (4th ed.). World Health Organization.
- World Health Organization. (2023). WHO consolidated guidelines on tuberculosis module 4: Treatment - Drug-resistant tuberculosis treatment (update). World Health Organization.
